PubMed:24134405 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":294,"end":308},"obj":"HP_0001298"}],"text":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings.\nOBJECTIVE: To determine the safety and efficacy of single dose systemic recombinant human erythropoietin (rEPO) in neonates with perinatal hypoxic Ischemic Encephalopathy (HIE), and its effect on serum brain-derived neurotrophic factor (BDNF) and neuron-specific enolase (NSE).\nMETHODS: Forty-five full-term neonates; 30 with perinatal HIE and 15 controls were studied. HIE neonates were randomized into three intervention groups (first 6 h of life): 10 received single subcutaneous 1500 U/kg rEPO at day-1, 10 subjected to hypothermia for 72 h and 10 received supportive care. BDNF and NSE measured during first 6 h and day 5 postnatal. Daily Thompson's score, MRI brain and neuromuscular function scale for survivors at 3 months of age were done.\nRESULTS: Hypothermia group had best survival especially with stage-II Sarnat scale, followed by rEpo and supportive group. BDNF day-5 was significantly higher in each group compared to controls. MRI score and neuromuscular function score were non-significantly lower in the hypothermia group compared to rEPO.\nCONCLUSIONS: Therapeutic hypothermia was superior to single dose rEpo for neuro-protection in HIE especially in patients with stage-II Sarnat scale. Therapeutic effect of combined rEPO multiple dosing and modest hypothermia therapy should be studied."}

{"project":"Allie","denotations":[{"id":"SS1_24134405_2_0","span":{"begin":210,"end":242},"obj":"expanded"},{"id":"SS2_24134405_2_0","span":{"begin":244,"end":248},"obj":"abbr"},{"id":"SS1_24134405_2_1","span":{"begin":277,"end":308},"obj":"expanded"},{"id":"SS2_24134405_2_1","span":{"begin":310,"end":313},"obj":"abbr"},{"id":"SS1_24134405_2_2","span":{"begin":340,"end":373},"obj":"expanded"},{"id":"SS2_24134405_2_2","span":{"begin":375,"end":379},"obj":"abbr"},{"id":"SS1_24134405_2_3","span":{"begin":385,"end":408},"obj":"expanded"},{"id":"SS2_24134405_2_3","span":{"begin":410,"end":413},"obj":"abbr"}],"relations":[{"id":"AE1_24134405_2_0","pred":"abbreviatedTo","subj":"SS1_24134405_2_0","obj":"SS2_24134405_2_0"},{"id":"AE1_24134405_2_1","pred":"abbreviatedTo","subj":"SS1_24134405_2_1","obj":"SS2_24134405_2_1"},{"id":"AE1_24134405_2_2","pred":"abbreviatedTo","subj":"SS1_24134405_2_2","obj":"SS2_24134405_2_2"},{"id":"AE1_24134405_2_3","pred":"abbreviatedTo","subj":"SS1_24134405_2_3","obj":"SS2_24134405_2_3"}],"text":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings.\nOBJECTIVE: To determine the safety and efficacy of single dose systemic recombinant human erythropoietin (rEPO) in neonates with perinatal hypoxic Ischemic Encephalopathy (HIE), and its effect on serum brain-derived neurotrophic factor (BDNF) and neuron-specific enolase (NSE).\nMETHODS: Forty-five full-term neonates; 30 with perinatal HIE and 15 controls were studied. HIE neonates were randomized into three intervention groups (first 6 h of life): 10 received single subcutaneous 1500 U/kg rEPO at day-1, 10 subjected to hypothermia for 72 h and 10 received supportive care. BDNF and NSE measured during first 6 h and day 5 postnatal. Daily Thompson's score, MRI brain and neuromuscular function scale for survivors at 3 months of age were done.\nRESULTS: Hypothermia group had best survival especially with stage-II Sarnat scale, followed by rEpo and supportive group. BDNF day-5 was significantly higher in each group compared to controls. MRI score and neuromuscular function score were non-significantly lower in the hypothermia group compared to rEPO.\nCONCLUSIONS: Therapeutic hypothermia was superior to single dose rEpo for neuro-protection in HIE especially in patients with stage-II Sarnat scale. Therapeutic effect of combined rEPO multiple dosing and modest hypothermia therapy should be studied."}

{"project":"PCI_RCT","denotations":[{"id":"T1","span":{"begin":277,"end":308},"obj":"DP"},{"id":"T2","span":{"begin":310,"end":313},"obj":"DP"},{"id":"T3","span":{"begin":80,"end":111},"obj":"DP"},{"id":"T4","span":{"begin":474,"end":477},"obj":"DP"},{"id":"T5","span":{"begin":1291,"end":1294},"obj":"DP"},{"id":"T6","span":{"begin":508,"end":511},"obj":"DP"},{"id":"T7","span":{"begin":210,"end":242},"obj":"CI"},{"id":"T8","span":{"begin":244,"end":248},"obj":"CI"},{"id":"T9","span":{"begin":631,"end":635},"obj":"CI"},{"id":"T10","span":{"begin":1262,"end":1266},"obj":"CI"},{"id":"T11","span":{"begin":1377,"end":1381},"obj":"CI"},{"id":"T12","span":{"begin":983,"end":987},"obj":"CI"},{"id":"T13","span":{"begin":1191,"end":1195},"obj":"CI"}],"text":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings.\nOBJECTIVE: To determine the safety and efficacy of single dose systemic recombinant human erythropoietin (rEPO) in neonates with perinatal hypoxic Ischemic Encephalopathy (HIE), and its effect on serum brain-derived neurotrophic factor (BDNF) and neuron-specific enolase (NSE).\nMETHODS: Forty-five full-term neonates; 30 with perinatal HIE and 15 controls were studied. HIE neonates were randomized into three intervention groups (first 6 h of life): 10 received single subcutaneous 1500 U/kg rEPO at day-1, 10 subjected to hypothermia for 72 h and 10 received supportive care. BDNF and NSE measured during first 6 h and day 5 postnatal. Daily Thompson's score, MRI brain and neuromuscular function scale for survivors at 3 months of age were done.\nRESULTS: Hypothermia group had best survival especially with stage-II Sarnat scale, followed by rEpo and supportive group. BDNF day-5 was significantly higher in each group compared to controls. MRI score and neuromuscular function score were non-significantly lower in the hypothermia group compared to rEPO.\nCONCLUSIONS: Therapeutic hypothermia was superior to single dose rEpo for neuro-protection in HIE especially in patients with stage-II Sarnat scale. Therapeutic effect of combined rEPO multiple dosing and modest hypothermia therapy should be studied."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":277,"end":308},"obj":"DP"},{"id":"T2","span":{"begin":310,"end":313},"obj":"DP"},{"id":"T3","span":{"begin":474,"end":477},"obj":"DP"},{"id":"T4","span":{"begin":508,"end":511},"obj":"DP"},{"id":"T5","span":{"begin":1291,"end":1294},"obj":"DP"},{"id":"T6","span":{"begin":80,"end":111},"obj":"DP"},{"id":"T7","span":{"begin":210,"end":242},"obj":"CI"},{"id":"T8","span":{"begin":244,"end":248},"obj":"CI"},{"id":"T9","span":{"begin":631,"end":635},"obj":"CI"},{"id":"T10","span":{"begin":1191,"end":1195},"obj":"CI"},{"id":"T11","span":{"begin":1377,"end":1381},"obj":"CI"},{"id":"T12","span":{"begin":12,"end":38},"obj":"CI"},{"id":"T13","span":{"begin":983,"end":987},"obj":"CI"},{"id":"T14","span":{"begin":1262,"end":1266},"obj":"CI"}],"text":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings.\nOBJECTIVE: To determine the safety and efficacy of single dose systemic recombinant human erythropoietin (rEPO) in neonates with perinatal hypoxic Ischemic Encephalopathy (HIE), and its effect on serum brain-derived neurotrophic factor (BDNF) and neuron-specific enolase (NSE).\nMETHODS: Forty-five full-term neonates; 30 with perinatal HIE and 15 controls were studied. HIE neonates were randomized into three intervention groups (first 6 h of life): 10 received single subcutaneous 1500 U/kg rEPO at day-1, 10 subjected to hypothermia for 72 h and 10 received supportive care. BDNF and NSE measured during first 6 h and day 5 postnatal. Daily Thompson's score, MRI brain and neuromuscular function scale for survivors at 3 months of age were done.\nRESULTS: Hypothermia group had best survival especially with stage-II Sarnat scale, followed by rEpo and supportive group. BDNF day-5 was significantly higher in each group compared to controls. MRI score and neuromuscular function score were non-significantly lower in the hypothermia group compared to rEPO.\nCONCLUSIONS: Therapeutic hypothermia was superior to single dose rEpo for neuro-protection in HIE especially in patients with stage-II Sarnat scale. Therapeutic effect of combined rEPO multiple dosing and modest hypothermia therapy should be studied."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T10","span":{"begin":310,"end":313},"obj":"DP"},{"id":"T11","span":{"begin":474,"end":477},"obj":"DP"},{"id":"T12","span":{"begin":508,"end":511},"obj":"DP"},{"id":"T13","span":{"begin":1291,"end":1294},"obj":"DP"},{"id":"T14","span":{"begin":80,"end":111},"obj":"DP"},{"id":"T15","span":{"begin":1262,"end":1266},"obj":"CI"},{"id":"T16","span":{"begin":983,"end":987},"obj":"CI"},{"id":"T17","span":{"begin":210,"end":242},"obj":"CI"},{"id":"T18","span":{"begin":12,"end":38},"obj":"CI"},{"id":"T5","span":{"begin":244,"end":248},"obj":"CI"},{"id":"T6","span":{"begin":631,"end":635},"obj":"CI"},{"id":"T7","span":{"begin":1191,"end":1195},"obj":"CI"},{"id":"T8","span":{"begin":1377,"end":1381},"obj":"CI"},{"id":"T9","span":{"begin":277,"end":308},"obj":"DP"}],"text":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings.\nOBJECTIVE: To determine the safety and efficacy of single dose systemic recombinant human erythropoietin (rEPO) in neonates with perinatal hypoxic Ischemic Encephalopathy (HIE), and its effect on serum brain-derived neurotrophic factor (BDNF) and neuron-specific enolase (NSE).\nMETHODS: Forty-five full-term neonates; 30 with perinatal HIE and 15 controls were studied. HIE neonates were randomized into three intervention groups (first 6 h of life): 10 received single subcutaneous 1500 U/kg rEPO at day-1, 10 subjected to hypothermia for 72 h and 10 received supportive care. BDNF and NSE measured during first 6 h and day 5 postnatal. Daily Thompson's score, MRI brain and neuromuscular function scale for survivors at 3 months of age were done.\nRESULTS: Hypothermia group had best survival especially with stage-II Sarnat scale, followed by rEpo and supportive group. BDNF day-5 was significantly higher in each group compared to controls. MRI score and neuromuscular function score were non-significantly lower in the hypothermia group compared to rEPO.\nCONCLUSIONS: Therapeutic hypothermia was superior to single dose rEpo for neuro-protection in HIE especially in patients with stage-II Sarnat scale. Therapeutic effect of combined rEPO multiple dosing and modest hypothermia therapy should be studied."}